Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy

Wang, Weiping; Liu, Xiaoliang; Hou, Xiaorong; Lian, Xin; Liu, Zhikai; Shen, Jie; Sun, Shibin; Yan, Jun; Zheng, Min; Wang, Dunhuang; Meng, Qinggyu; Fu, Jingxuan; Zhang, Fuquan; Qin, Jie; Hu, Ke

doi:10.1016/j.ygyno.2019.09.003

Cited by 20 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent retrospective study with a large sample size from our institution demonstrated that a preoperative serum SCC-Ag level > 2.75 ng/mL is an independent prognostic factor for progression-free survival in cervical squamous cell carcinoma patients with highrisk factors [23]. In addition, a recent study investigated the association between posttreatment SCC-Ag levels and survival in patients treated with concurrent chemoradiation [24]. Patients with posttreatment SCC-Ag ≥ 1.8 ng/mL had significantly poor survival [24].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, a recent study investigated the association between posttreatment SCC-Ag levels and survival in patients treated with concurrent chemoradiation [24]. Patients with posttreatment SCC-Ag ≥ 1.8 ng/mL had significantly poor survival [24].…”

Section: Discussionmentioning

confidence: 99%

“…The role of serum SCC-Ag in squamous cervical cancer has been extensively evaluated in previous works [4,7,8,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24], and several reviews and metaanalyses have been published in the literature [5,[25][26][27]. Most studies were of retrospective design and only detected SCC-Ag at one time-point.…”

Section: Introductionmentioning

confidence: 99%

“…Most studies were of retrospective design and only detected SCC-Ag at one time-point. They could be roughly divided into two groups according to the SCC-Ag measurement time: first, the clinical relevance of pretreatment SCC-Ag, which is still debated [4,5,14,15,18,20,[22][23][24], and second, the value of SCC-Ag in the monitoring of response to treatment and follow-up [7,8,17,18,20]. To date, few studies have investigated the dynamic change in serum SCC-Ag levels during treatment, from surgery to adjuvant therapies.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Sun

Kang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: To study the kinetic profile and clinicopathological implications of squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients who underwent surgery by a self-developed SCC-Ag single molecule assay (Simoa) prototype immunoassay. Methods: Participants were prospectively enrolled between 04/2016 and 06/2017. Consecutive serum samples were collected at five points: day 0 (the day before surgery), postoperative day 4, weeks 2-4, months 2-4 and months 5-7. In total, 92 patients and 352 samples were included. The kinetic change in SCC-Ag levels and their associations with clinicopathological characteristics were studied. Results: Simoa SCC-Ag was validated by comparison with the Architect assay. SCC-Ag levels measured by the Simoa assay were highly correlated with the Architect assay's levels (Pearson's correlation coefficient = 0.979, Passing-Bablok regression slope 0.894 (0.847 to 0.949), intercept − 0.009 (− 0.047 to 0.027)). The median values for each time-point detected by the Simoa assay were 2.49, 0.66, 0.61, 0.72, and 0.71 ng/mL, respectively. The SCC-Ag levels decreased dramatically after surgery and then stabilized and fluctuated to some extent within 6 months. Patients with certain risk factors had significantly higher SCC-Ag values than their negative counterparts before surgery and at earlier time points after surgery, while no difference existed at the end of observation. Furthermore, although patients with positive lymph nodes had sustained higher SCC-Ag levels compared to those with negative lymph nodes, similar kinetic patterns of SCC-Ag levels were observed after surgery. Patients who received postoperative treatment had significantly higher SCC-Ag values than those with surgery only at diagnosis, while no difference existed after treatment. Conclusions: The Simoa SCC-Ag prototype was established for clinical settings. The SCC-Ag levels were higher in patients with risk factors, whereas the kinetic trend of SCC-Ag might be mainly affected by postoperative adjuvant therapy. These data indicate that the SCC-Ag level might be a good predictor for the status of cervical cancer, including disease aggressiveness and treatment response.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Sun

Kang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…In approximately 80% of patients, recurrence of cervical cancer occurs within 2 years after initial treatment. Some prognostic factors have been associated with clinical outcomes, including age, stage, tumour pathology, primary tumour size, lymph node status, squamous cell carcinoma antigen, and human papillomavirus [3][4][5][6]. 18 F-FDG PET/CT has become an essential imaging tool in oncology in addition to conventional radiologic methods such as computed tomography (CT) and magnetic resonance imaging (MRI) [7].…”

Section: Introductionmentioning

confidence: 99%

The role of the metabolic parameters of pre-treatment 18F-FDG PET/CT in patients with locally advanced cervical cancer

Wang

Liu

Wang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Abstract Purpose The purpose of the present study was to evaluate the role of the pre-treatment metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in patients with locally advanced cervical cancer (LACC) treated with definitive concurrent chemoradiotherapy (CCRT) or radiotherapy. Methods Patients with LACC who underwent pre-treatment 18F-FDG PET/CT examination and definitive CCRT or radiotherapy between February 2010 and December 2015 in our institute were enrolled. For each patient, the maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) of the primary tumour were measured. The survival outcomes were calculated with the Kaplan-Meier method. Cox proportional hazards models were used for univariate and multivariate analyses. Results A total of 125 patients were finally included in this study. The median follow-up duration was 62 months (range, 4-114 months). The 5-year overall survival (OS), disease-free survival (DFS), local control (LC) and distant metastasis-free survival (DMFS) rates were 83.6%, 75.1%, 92.3% and 79.9%, respectively. Univariate analysis indicated that MTV ≥ 18.3 cm3 showed worse OS and DMFS; however, no significant differences were identified for OS and DMFS in multivariate analyses. TLG ≥ 113.4 implied worse DFS and DMFS. In multivariate analysis, TLG ≥ 113.4 was an independent predictive factor for OS, DFS and DMFS. SUVmax and SUVmean had no significant influence on OS, DFS, LC or DMFS in either univariate or multivariate analysis. Conclusion Pre-treatment TLG ≥ 113.4 was associated with a high incidence of disease recurrence and poor OS in patients with LACC.

show abstract

Elevated pretreatment squamous cell Carcinoma Antigen indicates unfavorable treatment outcomes in cervical cancer patients receiving definitive radiotherapy

Liu,

Wang,

Zeng

et al. 2023

Precision Radiation Oncology

Self Cite

View full text Add to dashboard Cite

ObjectiveTo investigate the prognostic value of pretreatment squamous cell carcinoma antigen (SCC Ag) levels for treatment failure prediction in patients with cervical cancer.MethodsA quantity of 985 patients satisfying the eligibility criteria were included, with a median follow‐up duration of 63.7 months. The optimal cutoff value for pretreatment SCC Ag levels was verified by the receiver operating characteristic (ROC) curve. Five‐year disease‐free survival (DFS), overall survival (OS), and local control (LC) rates were evaluated utilizing the Kaplan‐Meier method. Log‐rank test and Cox proportional hazards model was implemented to recognize independent prognostic predictors.ResultsThe optimal pretreatment SCC Ag cutoff value was 8.85 ng/mL. Patients with pretreatment SCC Ag levels ≥ 8.85 ng/mL presented significantly inferior 5‐year DFS (63.8% vs. 81.8%), OS (71.7% vs. 88.7%), and LC (80.5% vs. 91.0%) compared to those with levels < 8.85 ng/mL (all p < 0.001). The results of the multivariate analysis indicated that the pretreatment SCC Ag level was an independent predictor of treatment failure (HR,1.772; 95% CI, 1.366 to 2.299; p < 0.001).ConclusionPretreatment SCC Ag is an effective prognostic factor in patients with cervical cancer undergoing definitive radiotherapy, with a ROC‐identified cutoff value of 8.85 ng/mL and elevated SCC Ag indicates unfavorable outcomes.

show abstract

Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy

Cited by 20 publications

References 24 publications

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

The role of the metabolic parameters of pre-treatment 18F-FDG PET/CT in patients with locally advanced cervical cancer

Elevated pretreatment squamous cell Carcinoma Antigen indicates unfavorable treatment outcomes in cervical cancer patients receiving definitive radiotherapy

Contact Info

Product

Resources

About